OTS - Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research
2021. February 17. 13:00
Lugano, Switzerland, 17 February, 2021 (APA/OTS) - Timely
presentations of trial data will accelerate transition from
research to practice
- Picture is available at AP Images (http://www.apimages.com) -
ESMO, the leading organisation for medical oncology, launches
an important new service for rapidly disseminating research to
accelerate the transition of results into practice for the benefit
of cancer patients.
"In a world that runs fast, timeliness in bringing research
advances to patients is critical. The lessons that we have learnt
from the COVID-19 pandemic have taught us that we need to be
creative in sharing research results, and we certainly don't have
to wait for the two or three times in the year when major oncology
congresses take place," says Solange Peters, ESMO President.
ESMO Virtual Plenaries will combine concise presentations of
new data, insightful discussion and audience Q&A in live,
easy-to-access, 60-minute online sessions at convenient times
across time zones. They will remain available on OncologyPRO,
ESMO's online resource portal, for subsequent viewing.
Every month, latest, original scientific data will be presented
from randomised phase III oncology trials or phase II trials which
demonstrate remarkable therapeutic benefit, scientific insight or
progress in an area of unmet need.
"By timely presentation of clinical and scientific data, ESMO
Virtual Plenaries will be complementary to and enhance the value of
conventional scientific congresses, whilst adhering to the
principles of peer review, analysis and audience interaction," says
George Pentheroudakis, ESMO CMO.
Two abstracts maximum will be accepted for presentation each
month (except September and November when ESMO hosts major
congresses). Abstracts will be original data from international
investigators, selected by appropriate independent ESMO
specialists. After presentation in ESMO Virtual Plenaries,
abstracts will be published in Annals of Oncology and will be
eligible for encore presentation at the next ESMO Congress.
The first ESMO Virtual Plenary is Friday, 19 February, 1300 CET
Efficacy of everolimus in patients with HR+/HER2- high risk
early-stage breast cancer
The ESMO Virtual Plenaries are freely available to all
healthcare professionals working in Oncology. Anyone with an
already existing free ESMO Account will be able to access and watch.
ESMO Press Office
+41919731901
media@esmo.org
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.